 | • レポートコード：MRC2312MG08197 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の発作性夜間ヘモグロビン尿症治用療薬市場規模と予測を収録しています。・世界の発作性夜間ヘモグロビン尿症治用療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の発作性夜間ヘモグロビン尿症治用療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の発作性夜間ヘモグロビン尿症治用療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「エクリズマブ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 発作性夜間ヘモグロビン尿症治用療薬のグローバル主要企業は、Apellis Pharmaceuticals、 Alexion Pharmaceuticals Inc、 Akari Therapeutics Plc、 CinnaGen Co、 Ra Pharmaceuticals Inc、 Amgen Inc、 Achillion Pharmaceuticals Inc、 Alnylam Pharmaceuticals Inc、 F. Hoffmann-La Roche Ltd、 Novartis AG、 Regeneron Pharmaceuticals Inc、 BIOCAD、 Samsung Bioepis、 Amyndas Pharmaceuticals、 Teva Pharmaceutical Industries Ltd.、 LGM Pharma.、 Lannett、 NorthStar Rx LLC、 Abbott、 Par Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、発作性夜間ヘモグロビン尿症治用療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の発作性夜間ヘモグロビン尿症治用療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の発作性夜間ヘモグロビン尿症治用療薬市場：タイプ別市場シェア、2022年 ・エクリズマブ、ラブリズマブ、その他 世界の発作性夜間ヘモグロビン尿症治用療薬市場：用途別、2018年-2023年、2024年-2029年 世界の発作性夜間ヘモグロビン尿症治用療薬市場：用途別市場シェア、2022年 ・クリニック、病院、その他 世界の発作性夜間ヘモグロビン尿症治用療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の発作性夜間ヘモグロビン尿症治用療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における発作性夜間ヘモグロビン尿症治用療薬のグローバル売上、2018年-2023年 ・主要企業における発作性夜間ヘモグロビン尿症治用療薬のグローバル売上シェア、2022年 ・主要企業における発作性夜間ヘモグロビン尿症治用療薬のグローバル販売量、2018年-2023年 ・主要企業における発作性夜間ヘモグロビン尿症治用療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Apellis Pharmaceuticals、 Alexion Pharmaceuticals Inc、 Akari Therapeutics Plc、 CinnaGen Co、 Ra Pharmaceuticals Inc、 Amgen Inc、 Achillion Pharmaceuticals Inc、 Alnylam Pharmaceuticals Inc、 F. Hoffmann-La Roche Ltd、 Novartis AG、 Regeneron Pharmaceuticals Inc、 BIOCAD、 Samsung Bioepis、 Amyndas Pharmaceuticals、 Teva Pharmaceutical Industries Ltd.、 LGM Pharma.、 Lannett、 NorthStar Rx LLC、 Abbott、 Par Pharmaceutical ************************************************************* ・調査・分析レポートの概要 発作性夜間ヘモグロビン尿症治用療薬市場の定義 市場セグメント 世界の発作性夜間ヘモグロビン尿症治用療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の発作性夜間ヘモグロビン尿症治用療薬市場規模 世界の発作性夜間ヘモグロビン尿症治用療薬市場規模：2022年 VS 2029年 世界の発作性夜間ヘモグロビン尿症治用療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの発作性夜間ヘモグロビン尿症治用療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の発作性夜間ヘモグロビン尿症治用療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：エクリズマブ、ラブリズマブ、その他 発作性夜間ヘモグロビン尿症治用療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：クリニック、病院、その他 発作性夜間ヘモグロビン尿症治用療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別発作性夜間ヘモグロビン尿症治用療薬市場規模 2022年と2029年 地域別発作性夜間ヘモグロビン尿症治用療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Apellis Pharmaceuticals、 Alexion Pharmaceuticals Inc、 Akari Therapeutics Plc、 CinnaGen Co、 Ra Pharmaceuticals Inc、 Amgen Inc、 Achillion Pharmaceuticals Inc、 Alnylam Pharmaceuticals Inc、 F. Hoffmann-La Roche Ltd、 Novartis AG、 Regeneron Pharmaceuticals Inc、 BIOCAD、 Samsung Bioepis、 Amyndas Pharmaceuticals、 Teva Pharmaceutical Industries Ltd.、 LGM Pharma.、 Lannett、 NorthStar Rx LLC、 Abbott、 Par Pharmaceutical ... |
This research report provides a comprehensive analysis of the Paroxysmal Nocturnal Hemoglobinuria Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Paroxysmal Nocturnal Hemoglobinuria Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Paroxysmal Nocturnal Hemoglobinuria Drug, challenges faced by the industry, and potential opportunities for market players.
The global Paroxysmal Nocturnal Hemoglobinuria Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Paroxysmal Nocturnal Hemoglobinuria Drug market presents opportunities for various stakeholders, including Clinic, Hospital. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Paroxysmal Nocturnal Hemoglobinuria Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Paroxysmal Nocturnal Hemoglobinuria Drug market was valued at US$ 3018.2 million in 2022 and is projected to reach US$ 7363.5 million by 2029, at a CAGR of 13.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Paroxysmal Nocturnal Hemoglobinuria Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Market Overview: The report provides a comprehensive overview of the Paroxysmal Nocturnal Hemoglobinuria Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Eculizumab, Ravulizumab), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Paroxysmal Nocturnal Hemoglobinuria Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Paroxysmal Nocturnal Hemoglobinuria Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Paroxysmal Nocturnal Hemoglobinuria Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Paroxysmal Nocturnal Hemoglobinuria Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Paroxysmal Nocturnal Hemoglobinuria Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Paroxysmal Nocturnal Hemoglobinuria Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Paroxysmal Nocturnal Hemoglobinuria Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Eculizumab
Ravulizumab
Others
Market segment by Application
Clinic
Hospital
Others
Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Apellis Pharmaceuticals
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc
CinnaGen Co
Ra Pharmaceuticals Inc
Amgen Inc
Achillion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
BIOCAD
Samsung Bioepis
Amyndas Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
LGM Pharma.
Lannett
NorthStar Rx LLC
Abbott
Par Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Paroxysmal Nocturnal Hemoglobinuria Drug, market overview.
Chapter 2: Global Paroxysmal Nocturnal Hemoglobinuria Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Paroxysmal Nocturnal Hemoglobinuria Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Paroxysmal Nocturnal Hemoglobinuria Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Overall Market Size
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size: 2022 VS 2029
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Paroxysmal Nocturnal Hemoglobinuria Drug Players in Global Market
3.2 Top Global Paroxysmal Nocturnal Hemoglobinuria Drug Companies Ranked by Revenue
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Companies
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Companies
3.5 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Paroxysmal Nocturnal Hemoglobinuria Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Paroxysmal Nocturnal Hemoglobinuria Drug Players in Global Market
3.8.1 List of Global Tier 1 Paroxysmal Nocturnal Hemoglobinuria Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Paroxysmal Nocturnal Hemoglobinuria Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Markets, 2022 & 2029
4.1.2 Eculizumab
4.1.3 Ravulizumab
4.1.4 Others
4.2 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue & Forecasts
4.2.1 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2023
4.2.2 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2024-2029
4.2.3 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales & Forecasts
4.3.1 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2023
4.3.2 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2024-2029
4.3.3 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share, 2018-2029
4.4 By Type – Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2022 & 2029
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue & Forecasts
5.2.1 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2023
5.2.2 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2024-2029
5.2.3 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales & Forecasts
5.3.1 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2023
5.3.2 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2024-2029
5.3.3 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share, 2018-2029
5.4 By Application – Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2022 & 2029
6.2 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue & Forecasts
6.2.1 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2023
6.2.2 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2024-2029
6.2.3 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales & Forecasts
6.3.1 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2023
6.3.2 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2024-2029
6.3.3 By Region – Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2029
6.4.2 By Country – North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2029
6.4.3 US Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.4.4 Canada Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.4.5 Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2029
6.5.2 By Country – Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2029
6.5.3 Germany Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5.4 France Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5.5 U.K. Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5.6 Italy Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5.7 Russia Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5.8 Nordic Countries Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.5.9 Benelux Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2029
6.6.2 By Region – Asia Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2029
6.6.3 China Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.6.4 Japan Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.6.5 South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.6.6 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.6.7 India Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2029
6.7.2 By Country – South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2029
6.7.3 Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.7.4 Argentina Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales, 2018-2029
6.8.3 Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.8.4 Israel Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
6.8.6 UAE Paroxysmal Nocturnal Hemoglobinuria Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Apellis Pharmaceuticals
7.1.1 Apellis Pharmaceuticals Company Summary
7.1.2 Apellis Pharmaceuticals Business Overview
7.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.1.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.1.5 Apellis Pharmaceuticals Key News & Latest Developments
7.2 Alexion Pharmaceuticals Inc
7.2.1 Alexion Pharmaceuticals Inc Company Summary
7.2.2 Alexion Pharmaceuticals Inc Business Overview
7.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.2.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.2.5 Alexion Pharmaceuticals Inc Key News & Latest Developments
7.3 Akari Therapeutics Plc
7.3.1 Akari Therapeutics Plc Company Summary
7.3.2 Akari Therapeutics Plc Business Overview
7.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.3.5 Akari Therapeutics Plc Key News & Latest Developments
7.4 CinnaGen Co
7.4.1 CinnaGen Co Company Summary
7.4.2 CinnaGen Co Business Overview
7.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.4.4 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.4.5 CinnaGen Co Key News & Latest Developments
7.5 Ra Pharmaceuticals Inc
7.5.1 Ra Pharmaceuticals Inc Company Summary
7.5.2 Ra Pharmaceuticals Inc Business Overview
7.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.5.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.5.5 Ra Pharmaceuticals Inc Key News & Latest Developments
7.6 Amgen Inc
7.6.1 Amgen Inc Company Summary
7.6.2 Amgen Inc Business Overview
7.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.6.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.6.5 Amgen Inc Key News & Latest Developments
7.7 Achillion Pharmaceuticals Inc
7.7.1 Achillion Pharmaceuticals Inc Company Summary
7.7.2 Achillion Pharmaceuticals Inc Business Overview
7.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.7.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.7.5 Achillion Pharmaceuticals Inc Key News & Latest Developments
7.8 Alnylam Pharmaceuticals Inc
7.8.1 Alnylam Pharmaceuticals Inc Company Summary
7.8.2 Alnylam Pharmaceuticals Inc Business Overview
7.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.8.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.8.5 Alnylam Pharmaceuticals Inc Key News & Latest Developments
7.9 F. Hoffmann-La Roche Ltd
7.9.1 F. Hoffmann-La Roche Ltd Company Summary
7.9.2 F. Hoffmann-La Roche Ltd Business Overview
7.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.9.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.9.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.10 Novartis AG
7.10.1 Novartis AG Company Summary
7.10.2 Novartis AG Business Overview
7.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.10.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.10.5 Novartis AG Key News & Latest Developments
7.11 Regeneron Pharmaceuticals Inc
7.11.1 Regeneron Pharmaceuticals Inc Company Summary
7.11.2 Regeneron Pharmaceuticals Inc Business Overview
7.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.11.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.11.5 Regeneron Pharmaceuticals Inc Key News & Latest Developments
7.12 BIOCAD
7.12.1 BIOCAD Company Summary
7.12.2 BIOCAD Business Overview
7.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.12.4 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.12.5 BIOCAD Key News & Latest Developments
7.13 Samsung Bioepis
7.13.1 Samsung Bioepis Company Summary
7.13.2 Samsung Bioepis Business Overview
7.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.13.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.13.5 Samsung Bioepis Key News & Latest Developments
7.14 Amyndas Pharmaceuticals
7.14.1 Amyndas Pharmaceuticals Company Summary
7.14.2 Amyndas Pharmaceuticals Business Overview
7.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.14.4 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.14.5 Amyndas Pharmaceuticals Key News & Latest Developments
7.15 Teva Pharmaceutical Industries Ltd.
7.15.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.15.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.15.4 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.15.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
7.16 LGM Pharma.
7.16.1 LGM Pharma. Company Summary
7.16.2 LGM Pharma. Business Overview
7.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.16.4 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.16.5 LGM Pharma. Key News & Latest Developments
7.17 Lannett
7.17.1 Lannett Company Summary
7.17.2 Lannett Business Overview
7.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.17.4 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.17.5 Lannett Key News & Latest Developments
7.18 NorthStar Rx LLC
7.18.1 NorthStar Rx LLC Company Summary
7.18.2 NorthStar Rx LLC Business Overview
7.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.18.4 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.18.5 NorthStar Rx LLC Key News & Latest Developments
7.19 Abbott
7.19.1 Abbott Company Summary
7.19.2 Abbott Business Overview
7.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.19.4 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.19.5 Abbott Key News & Latest Developments
7.20 Par Pharmaceutical
7.20.1 Par Pharmaceutical Company Summary
7.20.2 Par Pharmaceutical Business Overview
7.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Major Product Offerings
7.20.4 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Revenue in Global (2018-2023)
7.20.5 Par Pharmaceutical Key News & Latest Developments
8 Global Paroxysmal Nocturnal Hemoglobinuria Drug Production Capacity, Analysis
8.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Production Capacity, 2018-2029
8.2 Paroxysmal Nocturnal Hemoglobinuria Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Paroxysmal Nocturnal Hemoglobinuria Drug Supply Chain Analysis
10.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Value Chain
10.2 Paroxysmal Nocturnal Hemoglobinuria Drug Upstream Market
10.3 Paroxysmal Nocturnal Hemoglobinuria Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
